Posted On: 11/22/2016 10:40:39 AM
Post# of 1460
Good news this morning, AVXL released data on the Phase 2a study and even though this study is supposed to be for dose optimization and safety, not efficacy, they have impressive data that seems like the drug stops progression of the disease. This is major because so far NOTHING has stabilized the disease like this.
And there were no serious adverse effects, and they say that it "appeared to be well tolerated."
Hopefully when they find out the optimal dose, this is something that will be rushed to approval (assuming Phase 3 data shows the same thing), given that there is NO drug now with this kind of safety profile. All of the current Alz drugs have potentially horrendous side effects, and they usually lose their efficacy after a few months or a year anyway.
And there were no serious adverse effects, and they say that it "appeared to be well tolerated."
Hopefully when they find out the optimal dose, this is something that will be rushed to approval (assuming Phase 3 data shows the same thing), given that there is NO drug now with this kind of safety profile. All of the current Alz drugs have potentially horrendous side effects, and they usually lose their efficacy after a few months or a year anyway.
(0)
(0)Scroll down for more posts ▼
